Adma Biologics, Inc. ADMA
We take great care to ensure that the data presented and summarized in this overview for ADMA BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADMA
View all-
Vanguard Group Inc Valley Forge, PA21MShares$326 Million0.0% of portfolio
-
Black Rock Inc. New York, NY18.6MShares$290 Million0.0% of portfolio
-
State Street Corp Boston, MA13.6MShares$211 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.5MShares$195 Million0.03% of portfolio
-
Sachem Head Capital Management LP New York, NY8.96MShares$139 Million5.63% of portfolio
-
Geode Capital Management, LLC Boston, MA5.81MShares$90.5 Million0.01% of portfolio
-
Nuveen, LLC Charlotte, NC5.72MShares$89.1 Million0.02% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.11MShares$79.5 Million0.34% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.8MShares$74.7 Million0.02% of portfolio
-
American Century Companies Inc Kansas City, MO4.7MShares$73.1 Million0.04% of portfolio
Latest Institutional Activity in ADMA
Top Purchases
Top Sells
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Transactions at ADMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.52%
|
$399,000
$19.79 P/Share
|
|
Dec 15
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.73%
|
$75,000
$5.4 P/Share
|
|
Nov 19
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.52%
|
$336,000
$16.0 P/Share
|
|
Nov 19
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.73%
|
$75,000
$5.4 P/Share
|
|
Oct 24
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.52%
|
$336,000
$16.0 P/Share
|
|
Oct 24
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.73%
|
$75,000
$5.4 P/Share
|
|
Sep 15
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.51%
|
$336,000
$16.13 P/Share
|
|
Sep 15
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.73%
|
$75,000
$5.4 P/Share
|
|
Aug 15
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.51%
|
$336,000
$16.88 P/Share
|
|
Aug 15
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.73%
|
$75,000
$5.4 P/Share
|
|
Jul 30
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,208
-0.25%
|
$21,744
$18.59 P/Share
|
|
Jul 30
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.51%
|
$20,000
$8.98 P/Share
|
|
Jul 24
2025
|
Brad L. Tade CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,123
-2.89%
|
$121,091
$17.31 P/Share
|
|
Jul 24
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,027
-0.62%
|
$51,459
$17.31 P/Share
|
|
Jul 15
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.51%
|
$378,000
$18.66 P/Share
|
|
Jul 15
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.72%
|
$75,000
$5.4 P/Share
|
|
Jun 26
2025
|
Brad L. Tade CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,838
-3.84%
|
$177,084
$18.4 P/Share
|
|
Jun 16
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.51%
|
$420,000
$20.81 P/Share
|
|
Jun 16
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.72%
|
$75,000
$5.4 P/Share
|
|
Jun 16
2025
|
Steve Elms |
SELL
Open market or private sale
|
Direct |
194,749
-69.04%
|
$3,894,980
$20.24 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 446K shares |
|---|---|
| Exercise of conversion of derivative security | 509K shares |
| Open market or private sale | 675K shares |
|---|---|
| Payment of exercise price or tax liability | 222K shares |
| Grant, award, or other acquisition | 10.9K shares |